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Abstract Beta-blockers are a highly promising treatment
modality for complicated infantile hemangiomas (IH).
However, data on propranolol as first-line treatment,
objective outcome measures and impact on hemodynamics
in young infants is limited. We retrospectively evaluated a
homogenous group of infants with proliferating complicated
IH treated with propranolol (2 mg/kg/day). Outcome was
assessed by blinded evaluation of clinical photographs by
visual analogue scale (VAS), ultrasound examination and
ophthalmological review (if appropriate). Tolerance and
hemodynamic variables were recorded over time, including
a 2-day in-patient observation at the initiation of therapy.
Twenty-five infants (median age 3.6 (1.5–9.1) months) were
included in the study. The median follow-up-time was 14 (9–
20) months and 14 patients completed treatment at a median
age of 14.3 (11.4–22.1) months, after a duration of 10.5 (7.5–
16) months. In all patients, there was significant fading of
colour (with a VAS of −9 (−6 to −9) after 7 months) and
significant decrease in size of the IH (with a VAS of −8 (−3 to
−10) after 7 months). Median thickness of the lesions
assessed by ultrasound at baseline and after 1 month was
14 (7–28) mm and 10 (5–23) mm, respectively (p<0.01). In
children with periocular involvement, astigmatism and
amblyopia resolved rapidly within 8 weeks. The overall
tolerance of propranolol was good, and no relevant
hemodynamic changes were noted. Conclusion: Our report
supports the excellent effect and good tolerance of this
novel therapy, and we propose the use of propranolol as
first-line treatment for IH.
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Introduction
Infantile hemangiomas (IH) are common, benign tumours,
occurring in 4–10% of infants [9]. They are usually
sporadic and show unique natural phases of proliferation
and involution. The majority of IH can be left untreated and
allowed to follow their natural course. However, a significant
proportion of hemangiomas are associated with substantial
morbidity in infancy and childhood [5]. IH that often require
treatment include those involving the periorbital area,
central face, airway, skin folds, anogenital area, sites at
high risk for ulceration, dysfunction or disfigurement [6].
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Systemic corticosteroids have been the mainstay of treat-
ment for more severe IH; however, the response is variable,
and side effects are insidious and difficult to monitor. More-
over, corticosteroids work best at stopping further growth, but
actual shrinkage only occurs in approximately one third of
patients [1]. Other treatment options for problematic IH
include intra-lesional corticosteroids, vincristine, interferon-
alpha, cyclophosphamide, laser, surgery or a combination of
these therapies. However, each of these modalities has
limited therapeutic benefit with its own side-effect profile
and potential serious risks [2, 15].
In 2008, Léauté-Labrèze et al. reported the incidental
finding that hemangiomas regress in children treated with
propranolol, a nonselective beta-blocker used in treating
infants with cardiac and renal conditions [12]. This report
has been met with great interest and enthusiasm and
physicians all over the world have started to use propranolol
for the treatment of problematic IH. Several case reports and
five published case series (including 23 to 58 patients each)
have since supported the apparent efficacy of propranolol for
IH [3, 10, 14, 17, 18]. The results of these observations are
highly promising, consistently reporting propranolol to be
effective and well tolerated for the treatment of IH, thus
superior to oral corticosteroids. However, these are non-
controlled studies, including heterogenous data regarding
patient age, dose of propranolol, previous or concomitant
treatment, monitoring and most of them lack objective
evaluation. Moreover, no detailed information has been
reported about the cardiovascular risks of propranolol in
children treated for IH. We aimed to determine the effect of
propranolol as first-line treatment for IH in a homogenous
group of patients by blinded evaluation of clinical photo-
graphs and ultrasound examination at fixed time points.
Using a standardised treatment protocol including a 2-day in-
patient observation at the initiation of therapy we docu-
mented data on hemodynamic parameters during treatment.
Materials and methods
Patients
We performed a retrospective chart review of patients who
were started on treatment with propranolol for problematic
IH between December 2008 and December 2009 at the
University Children’s Hospital Zurich. Problematic IH were
defined as hemangiomas with imminent impaired functional
or cosmetic outcome if left untreated. These patients would
have been treated with alternative methods (corticosteroids,
laser or surgery) without the available knowledge of the
efficacy of propranolol Only patients with proliferating IH
up to the maximum age of 9 months and a complete 2-day in-
hospital observation at the beginning of the treatment were
included. Patients with ongoing or previous corticosteroid
therapy were excluded. Consent to review patient case notes
and for the treatment with propranolol (off-label indication)
was received from all parents whose infants participated in this
study in accordance with our institutional ethical standards.
Treatment protocol
Our centre for vascular anomalies defined a standardised
protocol for the treatment of IH with propranolol in
collaboration with the paediatric cardiology team. The
following contraindications for the use of propranolol were
applied: history or risk of asthma, reactive airway disease,
impaired renal function, heart defects and arrhythmia with
contraindication for the use of beta-blockers, children with
central nervous system disorders, neonates under the age of
2 weeks and preterm babies before reaching a gestational
age of 40 weeks. Before the start of treatment, the protocol
included a clinical examination by a paediatric cardiologist,
echocardiography, electrocardiogram (ECG), recording of
baseline heart rate (HR) and blood pressure (BP), ultra-
sound examination (if possible due to the site of the lesion)
and clinical photographs. Patients were admitted for a 48–
72 h observation at initiation of treatment. On the first day,
oral propranolol was administered at a dose of 1 mg/kg/day,
divided in three doses, and increased to 2 mg/kg/day on the
second day, if tolerated well. The children’s HR and BP
were monitored 1 h after administration of each dose of the
medication and continuous HR monitoring was performed
during their sleep. After completing the second day of treat-
ment, the ECG, ultrasound of the lesion and photographs
were repeated and the patients discharged, continuing on
propranolol at 2 mg/kg/day, given in three doses per day.
Follow-up visits were performed after 1 week, 1 month and
every 2 months thereafter, including clinical examination,
measurement of HR, BP and clinical photographs. Ultra-
sound examination was performed again after 1 week and
1 month. Patients with periocular IH additionally had regular
ophthalmology reviews. The dose of propranolol was
adjusted to weight during follow-up. Therapy was continued
until the age of ≥12 months and weaned and stopped
thereafter according to the clinical response by reducing the
dose to 1 mg/kg/day for the last 4 weeks of treatment. Apart
from the medication with propranolol no alternative or
adjuvant therapies were performed.
Outcome measures
Digital photographs were taken by the same two hospital
photographers who produced standardised images, using
the same views and settings as in the baseline picture. The
images were assessed by an independent board-certified
dermatologist, who was unaware of the patient’s age and
494 Eur J Pediatr (2011) 170:493–501
treatment at the time of each photograph. The observer
documented changes in colour and size of the lesions on a
visual analogue scale (VAS) ranging from −10 to +10 by
comparing follow-up images to the baseline photograph pre
treatment. On the visual analogue scale 0 represented the
baseline photograph (pre-treatment), a decrease in colour or
size resulted in a—number, an increase in colour or size in
a + number.
If the location of the hemangiomas was amenable for
ultrasound examination the maximal thickness of the
lesions was measured by ultrasound (high resolution linear
transducers with frequences from 5 to 17 MHz) at the
above mentioned time points. The resistivity index as a
measure of blood flow was very variable in relation to the
activity of the patient and not consistently measured and
therefore not included in this analysis.
For periocular IH, the outcome was reviewed by a
board-certified paediatric ophthalmologist.
Adverse events were recorded by evaluation of the
recorded hemodynamic variables in comparison to age-
related normal values and the additional information in the
patient’s medical notes [8, 11, 16]. Hypotension was
defined accordingly (systolic or diastolic blood pressure
below the 5th centile for age) as follows [8, 11, 16]:
Age: 5th centile of
systolic BP:
5th centile of
diastolic BP:
0–3 months 57 mmHg 34 mmHg
3–6 months 71 mmHg 40 mmHg
6–9 months 85 mmHg 47 mmHg
9–12 months 87 mmHg 49 mmHg
12–36 months 90 mmHg 55 mmHg
Statistical analysis
Data collected from the patients’ charts, ultrasound exami-
nation and evaluation of photographs by VAS were entered
into a computerised database. Median and range were
calculated for continous values. The figures show boxplots
(without outliers and extremes). The Wilcoxon test was used
to compare two related samples, the Friedman test was
applied for repeated measures. The null hypothesis was
rejected with a two-sided p value of <0.05.
Results
Patients and treatment
Twenty-five patients with IH were included in the study.
The relevant epidemiologic and clinical characteristics of
the patients and details about the individual treatment
indication and duration are shown in Tables 1 and 2. The
female-to-male ratio was 1.8: 1. The median age at start of
treatment with propranolol was 3.6 (1.5–9.1) months. Three
patients (numbers 2, 9, 23) were previously preterm infants
born at 36 weeks of gestation and at initiation of treatment
they were all older than 40 weeks of gestation. Patient
number 3 was diagnosed with PHACE-syndrome (posterior
fossa anomalies, hemangioma, arterial lesions, cardiac
abnormalities, eye abnormalities). He had a large plaque-
type hemangioma on the left side of the face and a brain
magnetic resonance imaging scan showed hypoplasia of the
left internal carotid artery and an arachnoid cyst. Following
review by the cardiology and neurology team, it was felt
save to use propranolol in this patient.
At the time of initiation of treatment with propranolol,
no patient was on any concomitant therapy. In two infants
(numbers 13 and 19), laser therapy had been performed
earlier without success and their IH continued to increase in
size. All patients were treated with propranolol at a dose of
2 mg/kg/day. Fourteen patients completed treatment at
median age of 14.3 (11.4–22.1) months and after a median
treatment duration of 10.5 (7.5–16) months. Eleven patients
had ongoing therapy with propranolol at the time of writing
this paper (see Table 2). The median follow-up-time of all
patients was 14 (9–20) months.
Treatment response
All IH stopped growing, faded in colour and became
smaller (Fig. 1). VAS measurements of photographic
documentation were available at time points 0 (baseline),
2 days, 1 week, 1, 3, 5 and 7 months for 25, 25, 22, 24, 17,
14 and seven patients, respectively. Figure 2a and b
demonstrates the changes of VAS values for colour and
size of the lesions over time. There was significant fading
of colour and decrease in size of the IH during the follow-
up period compared to the photographs at baseline. Of note,
the VAS already decreased significantly within the first
2 days of therapy for both, colour and size. After 7 months
fading of colour was reached with a VAS of −9 (−6 to −9)
and shrinking of the lesions with a VAS of −8 (−3 to −10).
The two sub-groups of infants with deep (n=17) and
superficial, plaque-type hemangiomas (n=8) were com-
pared regarding their treatment response. The changes of
VAS did not differ significantly either for size or colour at
any of the time points between these two groups (data not
shown).
Twenty-four patients were examined by ultrasound at
baseline and during follow-up. The measurements of 11
patients were technically sufficient to be included for the
analysis. The reasons for exclusion of other patients were
difficulties in gaining reproducible readings due to the
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location of the IH, poor cooperation of the patient and
different examiners. Measurement of the thickness of the
IH proved to be the most reliable indicator for regression.
There were no changes of echogenicity observed during
regression. Figure 3 shows the decrease of hemangioma
thickness within the first month of treatment as assessed by
ultrasound examination. Median thickness of the lesions at
baseline and after 1 month were 14 (7–28) mm and 10 (5–23)
mm, respectively (p<0.01). All five ulcerated hemangiomas
healed completely within 2 weeks after start of treatment
with propranolol.
Six patients (numbers 1, 3, 4, 10, 18 and 23) had
periocular involvement of their IH. Four of them (numbers
3, 10, 18 and 23) presented with partial obstruction of the
visual axis and amblyopia in the preferential looking test. In
two children (numbers 4 and 10), unilateral astigmatism of
−1.5 and −2.0 diopters was noted due to the IH. After
baseline examination, standard occlusion therapy of the
unaffected eye was initiated in the four children with
amblyopia. At the same time, the children were started on
propranolol. Fast resolution of the visual axis obstruction
was noted in all of them and occlusion therapy could be
stopped after 1 to 6 months with no signs of amblyopia.
Astigmatism as well improved rapidly to −0.5 and −0.75
diopters with equal refraction in both eyes within a few
weeks to maximum 2 months.
In two of the 14 patients who completed treatment with
propranolol, mild re-growth and darkening of colour was
noted in their IH at 8 weeks after discontinuing therapy.
These patients (number 2 and 7) had been treated with
propranolol for a total of 11 and 8.5 months, and therapy
was stopped at the age of 14.3 and 12.5 months, respec-
tively. They were both re-started on propranolol and their
IH rapidly improved again.
Table 1 Clinical characteristics of all 25 patients
Patient
no.
Gender Type of
hemangioma
Localisation of
hemangioma
Age at start
propranolol
treatent (months)
Indication for
treatment
Duration of
propranolol
treatment (months)
Age at end of
propranolol
treatment (months)
Relapse after
propranolol
treatment
1 Male Plaque-type Infraorbital/cheek 4.0 Functional risk 11.0 15.0 No
2 Female Deep Parotid region and
forearm
3.3 Cosmetic risk 11.0 14.3 Yes
3 Male Plaque-type Left side of face,
phacea-syndrome
1.5 Functional risk 16.0 Ongoing .
4 Male Deep Infraorbital 2.2 Functional risk 16.0 18.2 No
5 Female Deep Nasal tip 5.3 Cosmetic risk 9.0 14.3 No
6 Male Deep Nasal tip 3.4 Cosmetic risk 11.0 Ongoing .
7 Female Plaque-type Philtrum 4.0 Cosmetic risk 8.5 12.5 Yes
8 Female Deep Perianal 8.4 Functional risk 9.0 17.4 No
9 Female Deep Parotid region 4.9 Cosmetic risk 14.0 Ongoing .
10 Male Plaque-type Periocular and
forehead
3.9 Functional risk 7.5 11.4 No
11 Male Deep Nasal tip 4.3 Cosmetic risk 12.0 16.3 No
12 Male Plaque-type Complete right arm 3.2 Cosmetic risk 10.0 13.2 No
13 Female deep Genital 9.1 Functional risk 13.0 22.1 No
14 Female Deep Nasal tip 6.8 Cosmetic risk 12.0 18.8 No
15 Female Deep Nose and temporal
region
3.3 Cosmetic risk 10.0 13.3 No
16 Female Plaque-type Nose 2.6 Cosmetic risk 10.0 Ongoing .
17 Female Deep Ear 2.0 Cosmetic risk 11.0 Ongoing .
18 Female Deep Upper eyelid 3.0 Functional risk 10.0 Ongoing .
19 Female Deep Upper lip 7.1 Cosmetic risk 10.0 Ongoing .
20 Female Deep Ear 2.9 Cosmetic risk 10.0 12.9 No
21 Female Deep Ear 2.0 Cosmetic risk 9.0 Ongoing .
22 Female Plaque-type Forehead 5.5 Cosmetic risk 9.0 Ongoing .
23 Male Deep Upper eyelid 2.3 Functional risk 12.0 14.3 No
24 Female Deep Head 8.3 Cosmetic risk 9.0 Ongoing .
25 Male Plaque-type Perianal, genital 3.6 Functional risk 9.0 Ongoing .
aPHACE, posterior fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities
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Hemodynamics and adverse events
As shown in Table 2, echocardiography performed at
baseline revealed a persistent foramen ovale in four patients.
Pre-treatment ECG was normal in all children except for
two patients, whose QT duration was mildly prolonged
(corrected QT interval of 455 and 456 ms, respectively).
We evaluated hemodynamic variables during the 2-day
in-patient observation at initiation of treatment. Baseline
values of HR, systolic and diastolic BP were compared with
the minimal values measured during the 2-day in-patient
stay, as shown in Fig. 4. At baseline, the HR was 121 (108–
150) bpm, systolic BP 86 (70–116) mmHg and diastolic BP
49 (30–71) mmHg compared to 100 (58–125) bpm, 76 (64–
110) mmHg and 45 (31–69) mmHg as minimal values during
the 2-day observation, respectively (p<0.05). Transient
bradycardia was noted in four patients. These episodes
occurred at night during sleep and were all self-limiting
without necessitating stimulation of the infant. Other vital
parameters (e.g. BP, oxygen saturation) were unremarkable
at the same time. In three infants with repeat short
bradycardia the dose of propranolol was increased slower
and in-patient observation prolonged up to 3 to 4 days. With
this regimen, bradycardias ceased in all patients, and they
were discharged at the intended propranolol dosage of
2 mg/kg/day. In six children, low blood pressure was
recorded during the first 48 h of treatment while the
infants were asleep. All six of them had a decreased
diastolic BP but only three of them had low systolic
values. However, these BP values were usually only 2–
10 mmHg below the normal age range and no patient
showed any concomitant symptoms.
ECG changes compared to baseline ECG were noted in
seven patients before discharge. All of these seven infants
had a mild prolongation of the PQ duration (PQ interval of
122 to 140 ms;). The prolonged corrected QT interval noted
as baseline remained unchanged in one patient and resolved
in the other.
Values of HR, systolic and diastolic BP at the time points
1 week, 1, 2, 5, 7 and 9 months were available in 24, 24,
17, 12 and eight patients, respectively. Figure 5 shows the
mean values of HR and BP during 7 months of treatment
with propranolol.
During follow-up, the following additional symptoms
were reported by the children’s parents: sleepiness (n=1),
sleep disturbances (n=1) and increased level of anxiety
(n=1). All of these symptoms were only reported at a
single follow-up visit and self-limiting thereafter. Overall
adverse events were all mild and transient and there was
no treatment drop-out of patients due to adverse events.
Neurologic follow-up of patient number three with PHACE-
syndrome revealed a global developmental delay of
5 month at the age of 16 months. This was felt to be
related to the PHACE-syndrome and the detected brain
abnormalities.
Discussion
Problematic hemangiomas require intervention to control
growth and reduce the likelihood of imminent functional
and cosmetic deformities [6]. Since the report of Léauté-
Labrèze et al. in 2008 propranolol has been widely used for
the treatment of problematic, although randomised con-
trolled studies have not been finished yet [12]. Propranolol
is a non-selective beta-receptor antagonist which has
previously been used in young infants for a variety of indi-
cations, such as hypertension, supraventricular tachycardia,
congestive heart failure and thyrotoxicosis [4]. Although
widely used now for the treatment of complicated IH, a
generally accepted concept of how propranolol works in IH
is lacking. Storch et al. recently summarised the current
Table 2 Summary of baseline characteristics and treatment of
children with hemangiomas
Patient characteristics and treatment n=25
Female-to-male ratio 1.8:1
Type of hemangioma
superficial/plaque-type 8
deep 17
Localisation of hemangioma
head 21
nose 7
periocular involvement 6
parotid area/ear involvement 5
perianal area 3
PHACEa-syndrome 1
Ulcerated hemangiomas 5
Echocardiogram pre-treatment
normal 21
persistent foramen ovale 4
Electrocardiogram pre-treatment
normal 23
abnormal 2
Age initiation of propranolol (months)
median (range) 3.6 (1.5–9.1)
Duration of propranolol treatment (months), n=25
median (range) 10 (7.5–16)
Age at end of propranolol treatment (months), n=14
median (range) 14.3 (11.4–22.1)
Duration of propranolol treatment until stopped, n=14
median (range) 10.5 (7.5–16)
aPHACE, posterior fossa anomalies, hemangioma, arterial lesions,
cardiac abnormalities, eye abnormalities
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Fig. 1 Photographic documentation of eight infants with problematic infantile hemangiomas during treatment with propranolol
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knowledge on the molecular mechanisms involved [19].
The striking effect of propranolol on growing IH can be
attributed to three molecular mechanisms: vasoconstriction,
inhibition of angiogenesis, and induction of apoptosis. They
correspond to early (brightening of hemangioma surface),
intermediate (growth arrest), and long-term (regression)
clinical observations.
Following the observation of Léauté-Labrèze et al.,
several case reports and five case series (including 23 to
58 patients each) have described the excellent effect of
propranolol for the treatment of IH [3, 10, 14, 17, 18].
However, in most of these series, propranolol was not used
as single therapy and a proportion of the reported patients
received concomitant systemic or intralesional steroids and
laser treatment [3, 14, 18]. In addition, varying age groups
of children and thus different stages of hemangiomas were
included in these studies and objective outcome measures
were limited or lacking. Sans et al. report the efficacy of
propranolol (dose 2–3 mg/kg/day) to be 100% in 32
patients, based on the individual judgement of the treating
physicians in most cases and additional ultrasound exami-
nation in 11 patients (34%) [18]. Based solely on the clinical
and photographic evaluation by the treating physicians
Laforgia et al. and Manunza et al. reported an excellent
response of propranolol (dose 2 mg/kg/day) for IH in 23
and 30 children, respectively [10, 14]. Qin ZP et al. in
China treated 58 children with propranolol (dose 1.0–
1.5 mg/kg/day) for IH [17]. The overall treatment response
was evaluated with the use of a four-point scale by the
treating physicians. The outcome was excellent in 17.2%,
good in 60.4% moderate in 20.7% and poor in 1.7% of
cases. Most recently, Buckmiller et al. evaluated 32 patients
treated with propranolol (dose 2 mg/kg/day) by clinical
examination (treating physicians) and assessment of photo-
graphs by blinded physicians, revealing 50% of patients to
be excellent responders, 47% partial responders and 3%
non-responders [3].
In our study, we included only infants with proliferating
hemangiomas who were exclusively treated with propranolol
Fig. 4 Hemodynamic variables during the 2-day in-patient observa-
tion at initiation of treatment with propranolol. Baseline values of
heart rate (HR, white boxes), systolic (SBP, light grey boxes) and
diastolic blood pressure (DBP, dark grey boxes) are shown in
comparison with the minimal values recorded (p<0.01 for HR and
SBP, p=0.03 for DBP)
Fig. 3 Change of hemangioma thickness measured by ultrasound
(US) in 11 patients during the first month of treatment (BL baseline; d
days; w week; m month); p<0.01
Fig. 2 Changes of VAS regarding colour (a) and size (b) of the
hemangiomas during follow-up and treatment with propranolol (BL
baseline; d days; w weeks; m months); p<0.01 for both parameters
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at a consistent dose of 2 mg/kg/day, according to a stan-
dardised protocol. Blinded evaluation of digital photographs
revealed significant fading of colour and decrease in size of
all IH. Unlike Qin et al., we did not find a significant
difference in response between deep and superficial haeman-
giomas in our small cohort [17]. However, it is our
impression that superficial hemangiomas in particular seem
to reach a certain plateau of response after approximately 7
to 8 months of treatment with characteristic residual
telangiectatic skin changes, whereas deep hemangiomas
(e.g. parotid hemangiomas) more likely completely resolve.
As an objective outcome measure, we included ultra-
sound examination of the IH. Reduction in IH thickness
proved to be the most reliable indicator for regression.
However, gaining reproducible ultrasound data of IH in this
cohort of young infants is challenging, depeding on size
and location of the lesion and cooperation of the patient.
The resistivity index as a measure of vascularity has been
used in the study by Sans et al., however we observed a
great variability of the resistivity index related to the
activity of the patients and therefore did not include this
variable [18]. The overall value of ultrasound assessment
for recording treatment response of IH remains unclear at
this stage.
For infants with periocular IH, ophthalmologic exami-
nation is an important and helpful monitoring measure
during treatment. In our opinion, the resolution of visual
axis obstruction, astigmatism and initial amblyopia was
substantially quicker than what we usually observed with
corticosteroid treatment. The general observation that
propranolol may induce a more rapid and greater clinical
improvement of IH than corticosteroids is supported by a
small recent retrospective comparative study (Powell J et
al., oral communication at the 18th Workshop of the
International Society for the Study of Vascular Anomalies
(ISSVA), Brussels, 2010) but needs to be confirmed in
larger comparative trials.
The true frequency of recurrence of IH after stopping
treatment with propranolol cannot be addressed by our limited
data. However, recurrences seem to occur in approximately
20–40% of cases [10, 18] (Phillips R et al. and Pope E et al.,
oral communications at the 18th Workshop of the Interna-
tional Society for the Study of Vascular Anomalies (ISSVA),
Brussels, 2010). Most interestingly, re-growth of IH’s after
stopping propranolol is also observed in children older than
12–14 months, thus at a time when the natural proliferation
phase is believed to be well completed. This unexpected
phenomenon raises the question whether treatment with
propranolol may delay the natural growth phase of IH.
Predictors of regrowth after stopping treatment remain to be
identified. However, as in our group, recurrences of IH are
usually mild and the patients respond well to re-treatment
with propranolol.
Although we found a significant decrease in HR and BP
during the 48-h in-patient observation at the start of
therapy, these changes were mild and not associated with
any symptoms. Of note, these values are probably also
explained by the children’s activity level at the time of
measurement and represent physiological differences.
Whereas baseline values originated from alert children
during daytime, the recorded minimal values were detected
at night during sleep. Regarding the blood pressure values it
needs to be considered that automated measurement of
diastolic BP often is inaccurate in this young age group.
Fig. 5 Heart rate (a white boxes, p=0.04), systolic (b light grey
boxes, p=0.09) and diastolic blood pressures (c dark grey boxes, 0.15)
during 7 months of treatment with propranolol (BL baseline; w week;
m months)
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This may limit adequate assessment of adverse effects. A
prolongation of the PQ duration, as noted in the ECG of
seven infants after starting treatment, represents the expected
effect of beta-blocking agents on the atrio-ventricular
node. Overall, no critical hemodynamic changes occurred
during treatment with propranolol. Frequency and nature
of adverse events observed in our cohort were similar to
other reports and overall considered to be minor [3, 10,
14, 17, 18].
During 40 years of clinical experience no serious
cardiovascular event was recorded for children on chronic
beta-blocker therapy [13]. Hypoglycaemia may occur due
to beta-blocking therapy and has recently been reported in
four infants treated for IH [7, 11]. We did not observe any
hypoglycaemia in our cohort; however, blood glucose
levels were not routinely measured. Of note, two of the
cases reported by Holland et al. had been on long-term
propranolol therapy before the episode of hypoglycaemia
occurred, without any known previous abnormalities of
blood glucose levels. Although hypoglycaemia seems to be
a rare adverse event physicians must be aware of the
potential for hypoglycaemia and propranolol should be
discontinued during inter-current illness, especially in the
setting of restricted oral intake. Overall adverse events
during propranolol treatment appear minor as compared to
the serious side effects of previous modalities for the
treatment of IH such as systemic corticosteroids and
interferon-alpha, which is associated with spastic diplegia
in up to 25% [13]. However, as propranolol evolves as a
new medical indication, careful monitoring is warranted.
This study is subject to a number of limitations: small
cohort of patients, retrospective and uncontrolled study
design, limited ultrasound values as objective outcome
measure. However, we believe this report adds further data
to demonstrate the high efficacy of propranolol as first-line
treatment for problematic IH. In addition, our detailed
analysis of cardiovascular variables supports the good
overall tolerance of this therapy in young infants.
Randomised-controlled studies with a large collective will
be helpful to more accurately investigate the efficacy and
safety of propranolol and reveal further information on
appropriate treatment dose and duration in particular.
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